References

10.1056/nejmoa1504030

10.1056/nejmoa1504030 · External reference

10.1056/nejmoa2407417

10.1056/nejmoa2407417 · External reference

10.1158/1078-0432.ccr-17-2267

10.1158/1078-0432.ccr-17-2267 · External reference

10.1056/nejmoa1709684

10.1056/nejmoa1709684 · External reference

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

10.1016/j.annonc.2021.03.204 · 2021 · External reference

Clinical and translational attributes of immune-related adverse events

10.1038/s43018-024-00730-3 · 2024 · External reference

10.1200/jco.2015.66.1389

10.1200/jco.2015.66.1389 · External reference

10.1200/jco.2005.06.205

10.1200/jco.2005.06.205 · External reference

10.1158/1078-0432.ccr-07-0187

10.1158/1078-0432.ccr-07-0187 · External reference

10.1200/jco.2015.60.8448

10.1200/jco.2015.60.8448 · External reference

Comprehensive Assessment of Prognostic Factors for Immune-Related Adverse Events in Immune Checkpoint Inhibitor-Treated Melanoma

10.3390/cancers17172806 · 2025 · External reference

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

10.1001/jamadermatol.2015.2707 · 2016 · External reference

10.1200/jco.2014.57.4756

10.1200/jco.2014.57.4756 · External reference

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis

10.1016/j.jaad.2021.03.094 · 2022 · External reference

10.1016/j.immuni.2026.01.001

10.1016/j.immuni.2026.01.001 · External reference

10.1001/archophthalmol.2011.302

10.1001/archophthalmol.2011.302 · External reference

Poliosis is associated with response to checkpoint-inhibitor therapy: a case report of two patients with multifocal metastatic melanoma

10.3390/immuno2020020 · 2022 · External reference

A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma

10.1111/bjd.15354 · 2018 · External reference

Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma

10.1097/iop.0000000000001451 · 2019 · External reference

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

10.1136/jitc-2023-007630 · 2023 · External reference

10.1101/2025.06.06.657162

10.1101/2025.06.06.657162 · External reference

10.1056/nejmra1703481

10.1056/nejmra1703481 · External reference

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

10.3389/fonc.2021.749064 · 2021 · External reference

10.1007/s00432-018-2819-x

10.1007/s00432-018-2819-x · External reference

Vitiligo and cutaneous melanoma. A case study

1991 · External reference

Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events

10.1016/j.jaad.2019.06.035 · 2020 · External reference

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit

10.1002/cncr.34004 · 2022 · External reference

Melanoma and Vitiligo: In Good Company

10.3390/ijms20225731 · 2019 · External reference

10.1016/j.ccell.2020.08.005

10.1016/j.ccell.2020.08.005 · External reference

10.1016/j.ccell.2021.11.012

10.1016/j.ccell.2021.11.012 · External reference

10.1007/s00262-011-1172-6

10.1007/s00262-011-1172-6 · External reference

Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy

10.3389/fimmu.2023.1197630 · 2023 · External reference

Image Gallery: Unilateral eyebrow depigmentation

10.1111/bjd.17638 · 2019 · External reference

Vasculitis and IgA monoclonal gammopathy of cutaneous significance

10.1111/jdv.14683 · 2018 · External reference

10.1046/j.1365-2133.2000.03464.x

10.1046/j.1365-2133.2000.03464.x · External reference

Immune niches for hair follicle development and homeostasis

10.3389/fphys.2024.1397067 · 2024 · External reference

10.1046/j.1087-0024.2003.00803.x

10.1046/j.1087-0024.2003.00803.x · External reference

Immune privilege of skin stem cells: What do we know and what can we learn?

10.1111/exd.14221 · 2021 · External reference

Melanocyte stem cells in the skin: Origin, biological characteristics, homeostatic maintenance and therapeutic potential

10.1002/ctm2.1720 · 2024 · External reference

Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance

10.1038/labinvest.2017.8 · 2017 · External reference

Resident memory T cells in the skin mediate durable immunity to melanoma

10.1126/sciimmunol.aam6346 · 2017 · External reference

Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data

10.3389/fonc.2022.1099108 · 2022 · External reference